Experience Leucine AI.
Powered Pharma Operations

Transform Your Pharma Operations with AI-Powered Intelligence. Experience how Leucine's integrated platform brings together manufacturing, quality, and laboratory operations in one digital ecosystem. Schedule a personalized demo to see how our AI solutions can optimize your processes, ensure compliance, and drive operational excellence.

See How AI Transforms Your Shop Floor Operations.
Experience firsthand how Leucine's 10x MES digitalizes batch records, streamlines production, and provides real-time monitoring of your manufacturing operations. Schedule a personalized demo to discover how our AI-powered platform can enhance your productivity while maintaining compliance.

Experience AI-Driven Quality Management in Action.
See how Leucine's 10x QMS automates compliance workflows, streamlines change control, and ensures regulatory adherence. Schedule a demo to learn how our AI-powered platform can help you manage quality processes more efficiently while reducing compliance risks.

Discover Smart Laboratory Operations Management.
Watch how Leucine's 10x LES orchestrates your lab operations, automates documentation, and ensures data integrity. Schedule a demo to see how our AI-powered platform can accelerate your testing processes while maintaining audit-readiness.

Optimize your manufacturing processes with paperless operations
Strengthen quality management and regulatory compliance
Accelerate laboratory operations and testing workflows

Connect with a Leucine Expert

Schedule a 30-Minute Product Demo with Expert Q&A

Sub System
Distribution

Analytics Overview

5
Form 483s Issued
2
483s converted to WL
6
Total Observation
Form 483s Issued
+74 from last period

Analytics Overview

Form 483 Conversion Rate by Year
Form 483s Issued (Yearly)

Recent Form 483s & Warning Letters

View all 483’s
Issue Date
Facility Name
Product Type
Form 483
Converted
Warning Letter
12 Jul 2024
Lonza Netherlands B.V.
Drugs
08 Sep 2023
Sichuan Deebio Pharmaceutical Co. Ltd.
Drugs
10 Mar 2023
Hugel, Inc. (Site 2)
Drugs
11 Feb 2022
Family Dollar Distribution Inc.
Drugs
20 Mar 2019
ACRX Specialty Pharmacy Inc
Drugs

Top Investigators

Investigator Name
Form 483 Count
Warning Letter Count
Margaret M Annes
2
2
Michael L Jones
2
2
Jocelyn C Turner
2
2
Lauren R Brady
2
2
Preston B Hoover
2
2
TITLE/ COMPANY Issue Date Status Details
The process (equipment and procedures) for the storage and shipment of commercial drug product (DP) has not been validated
Lonza Netherlands B.V.
12 Jul 2024 Normal Justification: Distribution processes are affected as they require validated methods for shipping drug products.
Excerpt: The proposed commercial DP shipping validation study has not been performed.
View Details
Control procedures are not established which validate the performance of distribution processes
Sichuan Deebio Pharmaceutical Co. Ltd.
08 Sep 2023 Normal Justification: Distribution is fundamentally linked to this observation as it involves the processes ensuring that the drug substance remains within specified conditions during shipping.
Excerpt: your firm ships USP drug substance with temperature storage specifications of (1) (b) (b) to (4) degrees Celsius for temperature, and (b) (4) % RH. There is no official validation study regarding the shipping container and components used which provide assurance that the (b) (4) USP drug substance in transit stays within its specified range for the duration of the shipment.
View Details
Your firm's quality unit's oversight of your GMP manufacturing operations is inadequate.
Hugel, Inc. (Site 2)
10 Mar 2023 Normal Justification: Unvalidated shipping conditions may affect sample integrity.
Excerpt: Shipping validations for samples tested in your contractor testing laboratories have not been conducted.
View Details
Distribution records do not contain the lot or control number of drug product
Family Dollar Distribution Inc.
11 Feb 2022 Normal Justification: The failure to record lot numbers directly impacts the Distribution process, as it is essential for tracking and tracing drug products throughout the supply chain.
Excerpt: Specifically, your firm does not document in your inventory control system the lot numbers of drug products received by your facility. In addition, your firm does not document the lot numbers of drug products that are shipped/distributed from your facility to your stores.
View Details
Drug products are not stored under appropriate conditions of temperature and humidity SO that their identity, strength, quality, and purity are not affected.
Family Dollar Distribution Inc.
11 Feb 2022 Normal Justification: The observation indicates a failure to maintain controlled environmental conditions in the warehouse, crucial for preserving drug product quality during storage.
Excerpt: Specifically, your firm does not monitor nor control temperature or humidity within your warehouse...
View Details

Prepare Better for FDA Audits with FDA Tracker

Get Real-time Insights: FDA 483s & Warning letters.
Uncover Trends: FDA Investigator profiles & Observations.
Stay Compliant: Manage risks proactively.